Synovial sarcoma: Defining features and diagnostic evolution

Annals of Diagnostic Pathology

Volumn 18, Issue 6, 2014, Pages 369-380

  Thway, Khin ^a   Fisher, Cyril ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Genetics; Histopathology; SS18 SSX; Synovial sarcoma; SYT; TLE1; Translocation

Indexed keywords

CYTOKERATIN 1; CYTOKERATIN 3; CYTOKERATIN 7; CYTOKERATIN 9; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; IFOSFAMIDE; NY ESO 1 ANTIGEN; PAZOPANIB; PROTEIN BCL 2; ONCOPROTEIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CHEMOSENSITIVITY; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; FUSION GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SPINDLE CELL; SYNOVIAL SARCOMA; TUMOR VOLUME; EPITHELIUM CELL; GENETICS; METABOLISM; PATHOLOGY; SARCOMA, SYNOVIAL;

CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; HUMANS; ONCOGENE PROTEINS, FUSION; SARCOMA, SYNOVIAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84923617290     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2014.09.002     Document Type: Review

References (189)

1. ShiW, Indelicato DJ, Morris CG, Scarborough MT, Gibbs CP, Zlotecki RA. Long-term treatment outcomes for patients with synovial sarcoma: A 40-year experience at the University of Florida. Am J Clin Oncol 2013;36: 83-8.
2. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005;27: 215-8.
3. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: An analysis of 1268 patients. Cancer 2009; 115: 3537-47.
4. McKinney CD, Mills SE, Fechner RE. Intraarticular synovial sarcoma. Am J Surg Pathol 1992;16: 1017-20.
5. Ishida T, Iijima T, Moriyama S, Nakamura C, Kitagawa T, Machinami R. Intraarticular calcifying synovial sarcoma mimicking synovial chondromatosis. Skeletal Radiol 1996;25: 766-9.
6. Dardick I, O'Brien PK, Jeans MT, Massiah KA. Synovial sarcoma arising in an anatomical bursa. Virchows Arch A Pathol Anat Histol 1982;397: 93-101.
7. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2: 401-21.
8. Smith ME, Fisher C, Wilkinson LS, Edwards JC. Synovial sarcoma lack synovial differentiation. Histopathology 1995;26: 279-81.
9. Ishibe T, Nakayama T, Aoyama T, Nakamura T, Toguchida J. Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res 2008; 466: 2147-55.
10. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 2007;11: 375-88.
11. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010;28: 1119-31.
12. Garcia CB, Shaffer CM, Alfaro MP, Smith AL, Sun J, Zhao Z, et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 2012;31: 2323-34.
13. Duband S, Morrison AL, Pasquier D, Coindre JM, Pasquier B, Peoc'h M. First case report of a fetal synovial sarcoma confirmed by molecular detection of SYT-SSX fusion gene transcripts. Am J Perinatol 2008;25: 517-20.
14. Przybyl J, Sciot R, Rutkowski P, Siedlecki JA, Vanspauwen V, Samson I, et al. Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: Description of three new cases. Tumour Biol 2012;33: 2245-53.
15. Chan JA, McMenamin ME, Fletcher CD. Synovial sarcoma in older patients: Clinicopathological analysis of 32 cases with emphasis on unusual histological features. Histopathology 2003;43: 72-83.
16. Speth BM, Krieg AH, Kaelin A, Exner GU, Guillou L, von Hochstetter A, et al. Synovial sarcoma in patients under 20 years of age: A multicenter study with a minimum follow-up of 10 years. J Child Orthop 2011;5: 335-42.
17. Okamoto S, Ishida T, Ohnishi H, MacHinami R, Hashimoto H. Synovial sarcomas of three children in the first decade: Clinicopathological and molecular findings. Pathol Int 2000;50: 818-23.
18. Kerouanton A, Jimenez I, Cellier C, Laurence V, Helfre S, Pannier S, et al. Synovial sarcoma in children and adolescents. J Pediatr Hematol Oncol 2014;36: 257-62.
19. Orbach D, Mc Dowell H, Rey A, Bouvet NA, Kelsey N, Stevens MC. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: Experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. Pediatr Blood Cancer 2011;57: 1130-6.
20. van de Rijn M, Barr FG, Xiong QB, Salhany KE, Fraker DL, Fisher C. Radiationassociated synovial sarcoma. Hum Pathol 1997;28: 1325-8.
21. Egger JF, Coindre JM, Benhattar J, Coucke P, Guillou L. Radiation-associated synovial sarcoma: Clinicopathologic and molecular analysis of two cases. Mod Pathol 2002; 15: 998-1004.
22. Deraedt K, Debiec-RychterM, Sciot R. Radiation-associated synovial sarcoma of the lung following radiotherapy for pulmonary metastasis of Wilms' tumour. Histopathology 2006;48: 473-5.
23. Lamovec J, Zidar A, Cucek-Plenicar M. Synovial sarcoma associated with total hip replacement. A case report. J Bone Joint Surg Am 1988;70: 1558-60.
24. Bakri A, Shinagare AB, Krajewski KM, Howard SA, Jagannathan JP, Hornick JL, et al. Synovial sarcoma: Imaging features of common and uncommon primary sites, metastatic patterns, and treatment response. AJR Am J Roentgenol 2012;199: W208-15.
25. Jones BC, Sundaram M, KransdorfMJ. Synovial sarcoma: MR imaging findings in 34 patients. AJR Am J Roentgenol 1993;161: 827-30.
26. Kransdorf MJ, Murphey MD. Radiologic evaluation of soft-tissue masses: A current perspective. AJR Am J Roentgenol 2000;175: 575-87.
27. Hirsch RJ, Yousem DM, Loevner LA, Montone KT, Chalian AA, Hayden RE, et al. Synovial sarcomas of the head and neck: MR findings. AJR Am J Roentgenol 1997;169: 1185-8.
28. Michal M, Fanburg-Smith JC, Lasota J, Fetsch JF, Lichy J, Miettinen M. Minute synovial sarcomas of the hands and feet: A clinicopathologic study of 21 tumors less than 1 cm. Am J Surg Pathol 2006;30: 721-6.
29. Flieder DB, Moran CA. Primary cutaneous synovial sarcoma: A case report. Am J Dermatopathol 1998;20: 509-12.
30. Al-Daraji W, Lasota J, Foss R, Miettinen M. Synovial sarcoma involving the head: Analysis of 36 cases with predilection to the parotid and temporal regions. Am J Surg Pathol 2009;33: 1494-503.
31. Suster S, Moran CA. Primary synovial sarcomas of the mediastinum: A clinicopathologic, immunohistochemical, and ultrastructural study of 15 cases. Am J Surg Pathol 2005;29: 569-78.
32. Witkin GB, Miettinen M, Rosai J. A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases. Am J Surg Pathol 1989;13: 490-9.
33. Cummings NM, Desai S, Thway K, Stewart S, Hill DA, Priest JR, et al. Cystic primary pulmonary synovial sarcoma presenting as recurrent pneumothorax: Report of 4 cases. Am J Surg Pathol 2010;34: 1176-9.
34. Nicholson AG, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: A clinicopathological and immunohistochemical review of three cases. Histopathology 1998;33: 508-13.
35. Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. Am J Surg Pathol 1996;20: 36-45.
36. Sakellaridis N, Mahera H, Pomonis S. Hemangiopericytoma-like synovial sarcoma of the lumbar spine. Case report. J Neurosurg Spine 2006;4: 179-82.
37. Nicholson AG, Rigby M, Lincoln C, Meller S, Fisher C. Synovial sarcoma of the heart. Histopathology 1997;30: 349-52.
38. Katakura H, Fukuse T, Shiraishi I, Hayatsu E, Nishijo K, Toguchida J, et al. Mediastinal synovial sarcoma. Thorac Cardiovasc Surg 2009;57: 183-5.
39. Fisher C, Folpe AL, Hashimoto H, Weiss SW. Intra-abdominal synovial sarcoma: A clinicopathological study. Histopathology 2004;45: 245-53.
40. Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, et al. Synovial sarcoma of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol 2008;32: 275-81.
41. Alsharief AN, Fageeh M, Alabdulkarim Y. Monophasic synovial sarcoma presenting as a primary ileal mass: A case report and review of the literature. J Med Case Rep 2012;6: 83.
42. Company Campins MM, Morales R, Dolz C, Garcia-Bonafe M, Vilella A, Huguet P. Primarymonophasic synovial sarcoma of the duodenum confirmed by cytogenetic analysis with demonstration of t(X;18): A case report. J Gastrointestin Liver Dis 2009;18: 89-93.
43. Schreiber-Facklam H, Bode-Lesniewska B, Frigerio S, Flury R. Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation. Hum Pathol 2007;38: 946-9.
44. Schoolmeester JK, Cheville JC, Folpe AL. Synovial sarcoma of the kidney: A clinicopathologic, immunohistochemical, and molecular genetic study of 16 cases. Am J Surg Pathol 2014;38: 60-5.
45. Jun L, Ke S, Zhaoming W, Linjie X, Xinru Y. Primary synovial sarcoma of the prostate: Report of 2 cases and literature review. Int J Surg Pathol 2008;16: 329-34.
46. Sumathi VP, Fisher C, Williams A, Meis J, Ganesan R, Kindblom LG, et al. Synovial sarcoma of the vulva and vagina: A clinicopathologic and molecular genetic study of 4 cases. Int J Gynecol Pathol 2011;30: 84-91.
47. Verbeke SL, Fletcher CD, AlberghiniM, Daugaard S, Flanagan AM, Parratt T, et al. A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am J Surg Pathol 2010; 34: 777-83.
48. Jung SC, Choi JA, Chung JH, Oh JH, Lee JW, Kang HS. Synovial sarcoma of primary bone origin: A rare case in a rare site with atypical features. Skeletal Radiol 2007; 36: 67-71.
49. KimKW, Park SY, Won KY, Jin W, KimSM, Park JS, et al. Synovial sarcoma of primary bone origin arising from the cervical spine. Skeletal Radiol 2013;42: 303-8.
50. Beck SE, Nielsen GP, Raskin KA, Schwab JH. Intraosseous synovial sarcoma of the proximal tibia. Int J Surg Oncol 2011;2011: 184891.
51. Cohen IJ, Issakov J, Avigad S, Stark B, Meller I, Zaizov R, et al. Synovial sarcoma of bone delineated by spectral karyotyping. Lancet 1997;350: 1679-80.
52. Sar C, Eralp L. Surgical treatment of primary tumors of the sacrum. Arch Orthop Trauma Surg 2002;122: 148-55.
53. Nakajo M, Ohkubo K, Nandate T, Shirahama H, Yanagi M, Anraku M, et al. Primary synovial sarcoma of the sternum: Computed tomography and magnetic resonance imaging findings. Radiat Med 2005;23: 208-12.
54. Tilakaratne WM. Synovial sarcoma of the mandible. J Oral Pathol Med 2006;35: 61-3.
55. Scheithauer BW, Amrami KK, Folpe AL, Silva AI, Edgar MA, Woodruff JM, et al. Synovial sarcoma of nerve. Hum Pathol 2011;42: 568-77.
56. Keith JL, Bilbao J, Croul S, Ang LC, GuiotMC, Rossiter J, et al. Clinical Neuropathology practice guide 6-2013: Morphology and an appropriate immunohistochemical screening panel aid in the identification of synovial sarcoma by neuropathologists. Clin Neuropathol 2013;32: 461-70.
57. Lin YJ, Yang QX, Tian XY, Li B, Li Z. Unusual primary intracranial dural-based poorly differentiated synovial sarcoma with t(X; 18)(p11; q11). Neuropathology 2013;33: 75-82.
58. Horbinski C, Cieply K, Bejjani GK, McFadden K. Primary intracranial dural-based synovial sarcoma with an unusual SYT fluorescence in situ hybridization pattern. J Neurosurg 2008;109: 897-903.
59. Xiao GY, Pan BC, Tian XY, Li Y, Li B, Li Z. Synovial sarcoma in cerebellum: A case report and literature review. Brain Tumor Pathol 2014;31: 68-75.
60. Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: Identification of low and high risk groups. Cancer 1999;85: 2596-607.
61. Krieg AH, Hefti F, Speth BM, Jundt G, Guillou L, Exner UG, et al. Synovial sarcomas usually metastasize after N5 years: A multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol 2011;22: 458-67.
62. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003;143: 1-31.
63. Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013;31: 608-15.
64. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: A clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000;18: 3794-803.
65. Deshmukh R, Mankin HJ, Singer S. Synovial sarcoma: The importance of size and location for survival. Clin Orthop Relat Res 2004;419: 155-61.
66. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101: 627-34.
67. Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000;18: 2087-94.
68. Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: Prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996;14: 1201-8.
69. LadanyiM, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multiinstitutional retrospective study of 243 patients. Cancer Res 2002;62: 135-40.
70. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcomaspecific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008; 14: 8191-7.
71. Takenaka S, Ueda T, Naka N, Araki N, Hashimoto N, Myoui A, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: A multi-institutional retrospective analysis in Japan. Oncol Rep 2008;19: 467-76.
72. Yaser S, Salah S, Al-Shatti M, Abu-Sheikha A, Shehadeh A, Sultan I, et al. Prognostic factors that govern localized synovial sarcoma: A single institution retrospective study on 51 patients. Med Oncol 2014;31: 958.
73. van de Rijn M, Barr FG, Xiong QB, Hedges M, Shipley J, Fisher C. Poorly differentiated synovial sarcoma: An analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 1999;23: 106-12.
74. Machen SK, Easley KA, Goldblum JR. Synovial sarcoma of the extremities: A clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas. Am J Surg Pathol 1999;23: 268-75.
75. Cagle LA, Mirra JM, Storm FK, Roe DJ, Eilber FR. Histologic features relating to prognosis in synovial sarcoma. Cancer 1987;59: 1810-4.
76. el-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, BallanceWW, Garnsey L, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer 1990;65: 2295-300.
77. Varela-Duran J, Enzinger FM. Calcifying synovial sarcoma. Cancer 1982;50: 345-52.
78. Golouh R, Stanta G, Bracko M, Bonin S. Correlation of MTS1/p16 and nm23 mRNA expression with survival in patients with peripheral synovial sarcoma. J Surg Oncol 2001;76: 83-8.
79. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol 2004; 22: 4040-50.
80. ten Heuvel SE, Hoekstra HJ, Bastiaannet E, Suurmeijer AJ. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: No role for SSX fusion type or ezrin expression. Appl Immunohistochem Mol Morphol 2009;17: 189-95.
81. Al-Hussaini H, Hogg D, Blackstein ME, O'Sullivan B, Catton CN, Chung PW, et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011;2011: 231789.
82. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014;11: 187-202.
83. Albritton KH, Randall RL. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol 2005;27: 219-22.
84. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005;16: 437-44.
85. Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2013. http://dx.doi.org/10.1038/onc.2013.443 [Epub ahead of print].
86. Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, et al. Deflection of VEGF action by SS18-SSX and composite VEGF- and CXCR4-targeted therapy in synovial sarcoma. Cancer Sci 2014. http://dx.doi.org/10.1111/cas.12469 [Epub ahead of print].
87. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
88. Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol 2012;23(Suppl. 10): X167-9.
89. Bloom JE, McNeel DG, Olson BM. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines 2012;11: 1401-4.
90. Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012;103: 1625-30.
91. Orenstein JM. Amianthoid fibers in a synovial sarcoma and a malignant schwannoma. Ultrastruct Pathol 1983;4: 163-76.
92. Tsuneyoshi M, Daimaru Y, Enjoji M. Malignant hemangiopericytoma and other sarcomas with hemangiopericytoma-like pattern. Pathol Res Pract 1984;178: 446-53.
93. Farris KB, Reed RJ.Monophasic, glandular, synovial sarcomas and carcinomas of the soft tissues. Arch Pathol Lab Med 1982;106: 129-32.
94. Majeste RM, Beckman EN. Synovial sarcoma with an overwhelming epithelial component. Cancer 1988;61: 2527-31.
95. Weidner N, Goldman R, Johnston J. Epithelioid monophasic synovial sarcoma. Ultrastruct Pathol 1993;17: 287-94.
96. Mirra JM, Wang S, Bhuta S. Synovial sarcoma with squamous differentiation of its mesenchymal glandular elements. A case report with light-microscopic, ultramicroscopic, and immunologic correlation. Am J Surg Pathol 1984;8: 791-6.
97. Povysil C. Synovial sarcoma with squamous metaplasia. Ultrastruct Pathol 1984;7: 207-13.
98. AmaryMF, Berisha F, Bernardi Fdel C, Herbert A, JamesM, Reis-Filho JS, et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: Analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol 2007;20: 482-96.
99. Milchgrub S, Ghandur-Mnaymneh L, Dorfman HD, Albores-Saavedra J. Synovial sarcoma with extensive osteoid and bone formation. AmJ Surg Pathol 1993;17: 357-63.
100. Hisaoka M, Matsuyama A, Shimajiri S, Akiba J, Kusano H, Hiraoka K, et al. Ossifying synovial sarcoma. Pathol Res Pract 2009;205: 195-8.
101. Vergara-Lluri ME, Stohr BA, Puligandla B, Brenholz P, Horvai AE. A novel sarcoma with dual differentiation: Clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 2012;36: 1093-8.
102. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15: 350-62.
103. Hornick JL, Fletcher CD.Myoepithelial tumors of soft tissue: A clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol 2003;27: 1183-96.
104. Miettinen M. Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol 1991;138: 505-13.
105. Lopes JM, Bjerkehagen B, Holm R, Bruland O, Sobrinho-Simoes M, Nesland JM. Immunohistochemical profile of synovial sarcoma with emphasis on the epithelialtype differentiation. A study of 49 primary tumours, recurrences and metastases. Pathol Res Pract 1994;190: 168-77.
106. Smith TA, Machen SK, Fisher C, Goldblum JR. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol 1999;112: 641-8.
107. HazelbagHM, van den Broek LJ, van Dorst EB, Offerhaus GJ, Fleuren GJ, Hogendoorn PC. Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: A comparison of various antigen retrieval systems using microwave heating and proteolytic pre-treatments. J Histochem Cytochem 1995;43: 429-37.
108. Fisher C. Synovial sarcoma: Ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol 1986; 17: 996-1008.
109. Abenoza P, Manivel JC, Swanson PE, Wick MR. Synovial sarcoma: Ultrastructural study and immunohistochemical analysis by a combined peroxidaseantiperoxidase/ avidin-biotin-peroxidase complex procedure. Hum Pathol 1986; 17: 1107-15.
110. Ordonez NG, Mahfouz SM, Mackay B. Synovial sarcoma: An immunohistochemical and ultrastructural study. Hum Pathol 1990;21: 733-49.
111. Wrba F, Fertl H, Amann G, Tell E, Krepler R. Epithelial markers in synovial sarcoma. An immunohistochemical study on paraffin embedded tissues. Virchows Arch A Pathol Anat Histopathol 1989;415: 253-8.
112. Jorgensen LJ, Lyon H, Myhre-Jensen O, Nordentoft A, Sneppen O. Synovial sarcoma. An immunohistochemical study of the epithelial component. APMIS 1994;102: 191-6.
113. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006;19: 659-68.
114. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22: 863-72.
115. Machen SK, Fisher C, Gautam RS, Tubbs RR, Goldblum JR. Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology 1998;33: 501-7.
116. Fisher C, Schofield JB. S-100 protein positive synovial sarcoma. Histopathology 1991;19: 375-7.
117. Fisher C, Montgomery E, Healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. Histopathology 2003;42: 588-93.
118. Pelmus M, Guillou L, Hostein I. Monophasic fibrous and poorly differentiated synovial sarcoma: Immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 2002;26: 1434-40.
119. Wong NA, Shelley-Fraser G. Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumour. Histopathology 2010;57: 250-8.
120. Doyle LA, Moller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL. MUC4 is a highly sensitive and specificmarker for low-grade fibromyxoid sarcoma. AmJ Surg Pathol 2011;35: 733-41.
121. Jagdis A, Rubin BP, Tubbs RR, PachecoM, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol 2009;33: 1743-51.
122. FragaMF, Berdasco M, Ballestar E, Ropero S, Lopez-Nieva P, Lopez-Serra L, et al. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. Cancer Res 2008;68: 4116-22.
123. Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007;31: 240-6.
124. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: A whole section study of 163 soft tissue and bone neoplasms.Mod Pathol 2009;22: 872-8.
125. Valente AL, Tull J, Zhang S. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma. Appl Immunohistochem Mol Morphol 2013;21: 408-13.
126. Chuang HC, Hsu SC, Huang CG, Hsueh S, Ng KF, Chen TC. Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma. Pathol Int 2013;63: 573-80.
127. FooWC, CruiseMW, WickMR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol 2011;135: 839-44.
128. Matsuyama A, Hisaoka M, Iwasaki M, Iwashita M, Hisanaga S, Hashimoto H. TLE1 expression in malignant mesothelioma. Virchows Arch 2010;457: 577-83.
129. Lai JP, Robbins PF, RaffeldM, Aung PP, Tsokos M, Rosenberg SA, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: Significance for NYESO- 1-based targeted therapy and differential diagnosis. Mod Pathol 2012;25: 854-8.
130. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001;94: 252-6.
131. Rekhi B, Sable M, Jambhekar NA. Histopathological, immunohistochemical andmolecular spectrum of myoepithelial tumours of soft tissues. Virchows Arch 2012; 461: 687-97.
132. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Matono H, Iwamoto Y, et al. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 2010;23: 981-90.
133. Billings SD, Walsh SV, Fisher C, Nusrat A, Weiss SW, Folpe AL. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: An immunohistochemical study with ultrastructural correlation. Mod Pathol 2004;17: 141-9.
134. Fisher C. The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: A study of 200 cases. Histopathology 1990;16: 441-54.
135. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999;91: 974-5.
136. CrewAJ, Clark J, Fisher C, Gill S, Grimer R, Shipley J, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14: 2333-40.
137. Lu YJ, Birdsall S, Summersgill B, Smedley D, Osin P, Fisher C, et al. Dual colour fluorescence in situ hybridization to paraffin-embedded samples to deduce the presence of the der(X)t(X;18)(p11.2;q11.2) and involvement of either the SSX1 or SSX2 gene: A diagnostic and prognostic aid for synovial sarcoma. J Pathol 1999; 187: 490-6.
138. Smith S, Reeves BR, Wong L, Fisher C. A consistent chromosome translocation in synovial sarcoma. Cancer Genet Cytogenet 1987;26: 179-80.
139. Reeves BR, Smith S, Fisher C, Warren W, Knight J, Martin C , et al. Characterization of the translocation between chromosomes X and 18 in human synovial sarcomas. Oncogene 1989;4: 373-8.
140. Saito T. The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: Relationship with extracellular matrix remodeling. Int J Clin Exp Pathol 2013;6: 2272-9.
141. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338: 153-60.
142. Fisher C. Soft tissue sarcomas with non-EWS translocations: Molecular genetic features and pathologic and clinical correlations. Virchows Arch 2010;456: 153-66.
143. Panagopoulos I, Mertens F, IsakssonM, Limon J, Gustafson P, Skytting B, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001;31: 362-72.
144. van de Rijn M, Barr FG, Collins MH, Xiong QB, Fisher C. Absence of SYT-SSX fusion products in soft tissue tumors other than synovial sarcoma. Am J Clin Pathol 1999; 112: 43-9.
145. Liew MA, Coffin CM, Fletcher JA, Hang MT, Tanito K, Niimura M, et al. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18). Pediatr Dev Pathol 2002;5: 165-9.
146. Shipley J, Crew J, Birdsall S, Gill S, Clark J, Fisher C, et al. Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma. Am J Pathol 1996;148: 559-67.
147. Thway K, Rockcliffe S, Gonzalez D, Swansbury J, Min T, Thompson L, et al. Utility of sarcoma-specific fusion gene analysis in paraffin-embedded material for routine diagnosis at a specialist centre. J Clin Pathol 2010;63: 508-12.
148. Torres L, Lisboa S, Cerveira N, Lopes JM, Lopes C, Teixeira MR. Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer Genet Cytogenet 2008;187: 45-9.
149. Dimitriadis E, Rontogianni D, Kyriazoglou A, Takou A, Frangia K, Pandis N, et al. Novel SYT-SSX fusion transcript variants in synovial sarcoma. Cancer Genet Cytogenet 2009;195: 54-8.
150. Sonobe H, Takeuchi T, Liag SB, Taguchi T, Yuri K, Shimizu K, et al. A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybrid SYT/SSX1 gene. Int J Cancer 1999;82: 459-64.
151. Brodin B, Haslam K, Yang K, Bartolazzi A, Xie Y, StarborgM, et al. Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression. Gene 2001;268: 173-82.
152. Storlazzi CT, Mertens F, Mandahl N, Gisselsson D, Isaksson M, Gustafson P, et al. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer 2003;37: 195-200.
153. Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: Characterization of 9 complete genes. Int J Cancer 2002;101: 448-53.
154. Middeljans E, Wan X, Jansen PW, Sharma V, Stunnenberg HG, Logie C. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PLoS One 2012;7: E33834.
155. Kato H, Tjernberg A, ZhangW, Wang L, Tsunematsu R, TsudaM, et al. SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem 2002;277: 5498-505.
156. Kimura T, Sakai M, Tabu K, Wang L, Tsunematsu R, Tsuda M, et al. Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration. Lab Invest 2009;89: 645-56.
157. Chittezhath M, Frump AL, Jourquin J, Lobdell N, Eid JE. The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells. Exp Cell Res 2008;314: 3551-62.
158. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20: 5755-62.
159. dos Santos NR, de Bruijn DR, Kater-Baats E, Otte AP, van Kessel AG. Delineation of the protein domains responsible for SYT, SSX, and SYT-SSX nuclear localization. Exp Cell Res 2000;256: 192-202.
160. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001;30: 1-14.
161. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: A potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006;66: 6919-27.
162. Barr FG, Zhang PJ. The impact of genetics on sarcoma diagnosis: An evolving science. Clin Cancer Res 2006;12: 5256-7.
163. Przybyl J, Jurkowska M, Rutkowski P, Debiec-Rychter M, Siedlecki JA. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma 2012;2012: 249219.
164. Fernebro J, Francis P, Eden P, Borg A, Panagopoulos I, Mertens F, et al. Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 2006; 118: 1165-72.
165. Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH, et al. Strong association of SYT-SSX fusion type andmorphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000;9: 1-8.
166. Birdsall S, Osin P, Lu YJ, Fisher C, Shipley J. Synovial sarcoma specific translocation associated with both epithelial and spindle cell components. Int J Cancer 1999;82: 605-8.
167. Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999;59: 3180-4.
168. Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000;13: 482-8.
169. Sun Y, Sun B, Wang J, Cai W, Zhao X, Zhang S, et al. Prognostic implication of SYTSSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci 2009;100: 1018-25.
170. Przybyl J, Sciot R, Wozniak A, Schoffski P, Vanspauwen V, Samson I, et al.Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. Int J Biochem Cell Biol 2014;53: 505-13. http://dx.doi. org/10.1016/j.biocel.2014.05.006 [Epub 2014 May 16].
171. Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, et al. Longterm survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer 2008;98: 474-9.
172. Hollmann TJ, Hornick JL. INI1-deficient tumors: Diagnostic features and molecular genetics. Am J Surg Pathol 2011;35: E47-63.
173. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009;33: 542-50.
174. Gleason BC, Fletcher CD. Myoepithelial carcinoma of soft tissue in children: An aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol 2007;31: 1813-24.
175. MiettinenM, Limon J, Niezabitowski A, Lasota J. Calretinin and othermesothelioma markers in synovial sarcoma: Analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25: 610-7.
176. Woodruff JM. Peripheral nerve tumors showing glandular differentiation (glandular schwannomas). Cancer 1976;37: 2399-413.
177. Christensen WN, Strong EW, Bains MS, Woodruff JM. Neuroendocrine differentiation in the glandular peripheral nerve sheath tumor. Pathologic distinction from the biphasic synovial sarcoma with glands. Am J Surg Pathol 1988;12: 417-26.
178. Kang Y, Pekmezci M, Folpe AL, Ersen A, Horvai AE. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol 2014;27: 55-61.
179. Fisher C, Carter RL, Ramachandra S, Thomas DM. Peripheral nerve sheath differentiation in malignant soft tissue tumours: An ultrastructural and immunohistochemical study. Histopathology 1992;20: 115-25.
180. LadanyiM, Woodruff JM, Scheithauer BW, Bridge JA, Barr FG, GoldblumJR, et al. Re: O'Sullivan MJ, KyriakosM, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod pathol 2000;13: 1336-46. Mod Pathol 2001;14: 733-7.
181. O'SullivanMJ, KyriakosM, Zhu X, WickMR, Swanson PE, Dehner LP, et al. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod Pathol 2000;13: 1336-46.
182. Sheng WQ, Hashimoto H, Okamoto S, Ishida T, Meis-Kindblom JM, Kindblom LG, et al. Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarcoma suggests a close relationship to dermatofibrosarcoma protuberans. J Pathol 2001;194: 88-94.
183. MiettinenM, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases. Am J Surg Pathol 2009;33: 1401-8.
184. Sheng WQ, Hisaoka M, Okamoto S, Tanaka A, Meis-Kindblom JM, Kindblom LG, et al. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffinembedded tissues. Am J Clin Pathol 2001;115: 348-55.
185. Fetsch JF, Laskin WB, Michal M, Remotti F, Heffner D, Ellis G, et al. Ectopic hamartomatous thymoma: A clinicopathologic and immunohistochemical analysis of 21 cases with data supporting reclassification as a branchial anlage mixed tumor. Am J Surg Pathol 2004;28: 1360-70.
186. Fetsch JF, Weiss SW. Ectopic hamartomatous thymoma: Clinicopathologic, immunohistochemical, and histogenetic considerations in four new cases. Hum Pathol 1990;21: 662-8.
187. Folpe AL, Lloyd RV, Bacchi CE, Rosai J. Spindle epithelial tumor with thymus-like differentiation: A morphologic, immunohistochemical, and molecular genetic study of 11 cases. Am J Surg Pathol 2009;33: 1179-86.
188. Folpe AL, Hill CE, Parham DM, O'Shea PA, Weiss SW. Immunohistochemical detection of FLI-1 protein expression: A study of 132 round cell tumorswith emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000;24: 1657-62.
189. Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 1997;21: 130-46.